49 results about "Hemolytic anemia" patented technology

Methods for treating subjects having complement-mediated hemolytic disorders, such as paroxysmal nocturnal hemoglobinuria (PNH) and other hemolytic anemias, the method comprising administering an effective amount of a composition that inhibits the activity of the complement alternative pathway.

Methods and compositions are provided which contains preparations of calcium chelators, bisphosphonates, antibiotics, antimicrobial agents, cytostatic agents, calcium ATPase and pyrophosphatase pump inhibitors, calcium phosphate-crystal dissolving agents, agents effective against calcium phosphate-crystal nucleation and crystal growth, and/or a combination of supportive agents and which may be used for treating and or reducing pathological calcifications, the growth of Nanobacterium and calcification-induced diseases including, but not limited to, Arteriosclerosis, Atherosclerosis, Coronary Heart Disease, Chronic Heart Failure, Valve Calcifications, Arterial Aneurysms, Calcific Aortic Stenosis, Transient Cerebral Ischemia, Stroke, Peripheral Vascular Disease, Vascular Thrombosis, Dental Plaque, Gum Disease (dental pulp stones), Salivary Gland Stones, Chronic Infection Syndromes such as Chronic Fatigue Syndrome, Kidney and Bladder Stones, Gall Stones, Pancreas and Bowel Diseases (such as Pancreatic Duct Stones, Crohn's Disease, Colitis Ulcerosa), Liver Diseases (such as Liver Cirrhosis, Liver Cysts), Testicular Microliths, Chronic Calculous Prostatitis, Prostate Calcification, Calcification in Hemodialysis Patients, Malacoplakia, Autoimmune Diseases. Erythematosus, Scleroderma, Dermatomyositis, Antiphospholipid Syndrome, Arteritis Nodosa, Thrombocytopenia, Hemolytic Anemia, Myelitis, Livedo Reticularis, Chorea, Migraine, Juvenile Dermatomyositis, Grave's Disease, Hypothyreoidism, Type 1 Diabetes Mellitus, Addison's Disease, Hypopituitarism, Placental and Fetal Disorders, Polycystic Kidney Disease, Glomerulopathies, Eye Diseases (such as Corneal Calcifications, Cataracts, Macular Degeneration and Retinal Vasculature-derived Processes and other Retinal Degenerations, Retinal Nerve Degeneration, Retinitis, and Iritis), Ear Diseases (such as Otosclerosis, Degeneration of Otoliths and Symptoms from the Vestibular Organ and Inner Ear (Vertigo and Tinnitus)), Thyroglossal Cysts, Thyroid Cysts, Ovarian Cysts, Cancer (such as Meningiomas, Breast Cancer, Prostate Cancer, Thyroid Cancer, Serous Ovarian Adenocarcinoma), Skin Diseases (such as Calcinosis Cutis, Calciphylaxis, Psoriasis, Eczema, Lichen Ruber Planus), Rheumatoid Arthritis, Calcific Tenditis, Osteoarthritis, Fibromyalgia, Bone Spurs, Diffuse Interstitial Skeletal Hyperostosis, Intracranial Calcifications (such as Degenerative Disease Processes and Dementia), Erythrocyte-Related Diseases involving Anemia, Intraerythrocytic Nanobacterial Infection and Splenic Calcifications, Chronic Obstructive Pulmonary Disease, Broncholiths, Bronchial Stones, Neuropathy, Calcification and Encrustations of Implants, Mixed Calcified Biofilms, and Myelodegenerative Disorders (such as Multiple Sclerosis, Lou Gehrig's and Alzheimer's Disease) in humans and animals. The method comprises administering the various classes of compositions of the present invention, which together effectively inhibit or treat the development of calcifications in vivo.

A compound of ferrous L-threonate with structure (I), its compostions and methods useful for iron supplementation for mammals, particularly for human body to improve and treat nutritional iron-deficiency anemia, blood loss anemia and hemolytic anemia.

The present invention is directed to a novel methods and compositions for the therapeutic intervention of vascular complications associated with diabetes, hyperlipidemias, and various cardiovascular disorders including but not limited to recalcitrant hypertension, coronary artery disease, pulmonary arterial hypertension, congestive heart failure, and hemolytic anemias. More specifically, the specification describes methods and compositions for treating such vascular disorders using compositions comprising BH4 and derivative thereof. Combination therapies of BH4 and other therapeutic regimens are contemplated.

The invention provides a use of chlorogenic acid in preparing medicament for treating thrombocytopenia and anemia and also provides a pharmaceutical composition containing the chlorogenic acid as the active constituent. The chlorogenic acid can treat anemia caused by various reasons, wherein the anemia contains post-hemorrhagic anemia, hemolytic anemia, macrocytic anemia and aplastic anemia.

The present invention is directed to pharmaceutical compositions and methods of using combination therapies containing a SYK inhibitor, or a pharmaceutically acceptable salt thereof, and a antineoplastic or antiinflammatory agent for the treatment of inflammatory, autoimmune and cell proliferative diseases, such as allergic reaction, transplant rejection, rheumatoid arthritis (RA), lupus, multiple sclerosis (MS) or psoriasis undesired acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL) (including diffuse large B cell lymphoma (DLBCL)), mantle cell lymphoma, acute lymphocytic leukemia (ALL), follicular lymphoma, Burkitt's lymphoma, small Lymphocytic (SLL), Lymphoma, multiple myeloma, asthma, vasculitis, Idiopathic thrombocytopenic purpura (ITP), Heparin Induced Thrombocytopenia (HIT) and hemolytic anemia.

The present invention provides substituted humanized, chimeric or human anti-CD20 antibodies or antigen binding fragments thereof and bispecific antibodies or fusion proteins comprising the substituted antibodies or antigen binding fragments thereof. The antibodies, fusion proteins or fragments are useful for treatment of B-cell disorders, such as B-cell malignancies and autoimmune diseases, as well as GVHD, organ transplant rejection, and hemolytic anemia and cryoglobulinemia. Amino acid substitutions, particularly substitution of an aspartate residue at Kabat position 101 of CDR3 VH (CDRH3), result in improved therapeutic properties, such as decreased dissociation rates, improved CDC activity, improved apoptosis, improved B-cell depletion and improved therapeutic efficacy at very low dosages. Veltuzumab, a humanized anti-CD20 antibody that incorporates such sequence variations, exhibits improved therapeutic efficacy compared to similar antibodies of different CDRH3 sequence, allowing therapeutic effect at dosages as low as 200 mg or less, more preferably 100 mg or less, more preferably 80 mg or less, more preferably 50 mg or less, most preferably 30 mg or less of naked antibody when administered i.v. or s.c.

The invention discloses a medicament-induced hemolytic anemia detection kit and also discloses a detection method using the kit. When plasma and antibody release liquid of a patient generate a positive reaction with corresponding medicament-sensitized erythrocytes, the plasma and the antibody release liquid of the patient generate a negative reaction with unsensitized erythrocytes; or a medicament is added into the plasma, the plasma or medicament antibodies in the antibody release liquid generates a positive reaction with normal erythrocytes, the plasma which is not added with the medicament or a dispersion solution generate a negative reaction with the normal erythrocytes. The medicament species causing the hemolytic anemia can be diagnosed accurately according to the results so as to guide to correctly select appropriate medicaments for treating the patient in clinic. The method has high accuracy, and is applicable to the detection by a test tube method or a microcolumn gel card method.

Method for diagnosis of autoimmune diseases of the GSE-type or associated with gluten sensitive enteropathy comprising taking a sample and testing the sample for antibodies against human tissue transglutaminase, tissue-specific transglutaminases, or other transglutaminases. It was found that autoimmune diseases other than celiac disease can be diagnosed and distinguished in this way, notably, dermatitis herpetiformis Duhring, Crohn's disease, Addison's disease, AI hemolytic anemia, AI thrombocytopenic purpura, AI thyroid diseases, atrophic gastritis—pernicious anemia, IgA nephropathy or IgA glomerulonephritis, myasthenia gravis, partial lipodystrophy, polymyositis, primary biliary cirrhosis, primary sclerosing cholangitis, recurrent pericarditis, relapsing polychondritis, rheumatoid arthritis, rheumatism, sarcoidosis, Sjögren's syndrome, SLE, splenic atrophy, type I (insulin-dependent) diabetes mellitus, diabetes mellitus of other types, ulcerative colitis, vasculitis (both systemic and cutaneous), vitiligo as well as autoimmune diseases associated with infertility, increased risk of abortion, or reduced fetal growth.

Compositions including a fatty acid, such as an odd chain fatty acid or a very long even chain fatty acid, and salts and derivatives thereof, and methods for treatment and prophylaxis of conditions related to anemic conditions, are provided, including compositions and methods for treating anemic conditions such as hemolytic anemia and anemia of chronic disease, and other related conditions.

The Efb protein from Staphylococcus aureus has now been shown to have the ability to bind to the C3 protein which is a crucial component in the activation of complement, and a specific C3 binding region has been located at the C-terminal end of the Efb protein. Isolated proteins and protein fragments containing the Efb protein C3 binding region are thus provided which have complement inhibiting activity, and these proteins and fragments are particularly useful in therapeutic methods wherein the inhibition of complement is desirable, such as in the treatment of hemolytic anemia, the prevention of graft or implant rejection, and to alleviate complement activation that is associated with kidney dialysis methods such as hemodialysis.

The invention relates to a medicine for treating erythronoclastic anemia, and belongs to the technical field of medicines. The medicine is used for solving a treatment problem of erythronoclastic anemia, and mainly comprises the following traditional Chinese medicines in parts by mass: 15 parts of mulberry fruit, 15 parts of leech, 15 parts of prepared rehmannia root, 10 parts of seaweed, 15 parts of all-grass of madras grangea, 15 parts of codonopsis pilosula, 10 parts of Chinese date, 18 parts of twotooth achyranthes root, 15 parts of turtle shell, 15 parts of milkvetch root, 20 parts of Chinese yam and 7 parts of licorice root. The medicine for treating erythronoclastic anemia has the characteristics of a pharmaceutical composition with effects of nourishing blood, activating blood circulation, tonifying kidney, strengthening liver essence and nourishing blood, and achieves a significant and stable curative effect.

The invention discloseshemogenesis Chinese medicine oral liquid. The liquid is prepared from, by weight, 80-100 parts of a Chinese medicine formula, 20-26 parts of a ferrous fumarate gel solution, 3-5parts of chlorophyll iron sodium salt, 0.3-0.5 part of vitamin C, 10-12 parts of sucrose, 0.05-0.06 part of a paraben ethyl ester and 2-3 parts of an ethanol; the invention also discloses a preparation method and application of the hemogenesisChinese medicine oral liquid. The method adds an appropriate amount of the ferrous fumarate gel solution by using a Chinese medicine formula preparation asthe main component of the oral liquid, and is supplemented with the chlorophyll iron sodium salt and the vitamin C, the vitamin C can promote a body to absorb iron elements in ferrous fumarate, and the preparedoral liquid can nourish yin and tonify a kidney, tonify qi and bloodand promote blood circulation and stop bleeding, and havethe significant effect on the symptoms of anemia such as aplasticanemia, iron deficiency anemia, malnutrition anemia, hemolytic anemia, chronic disease anemia, thrombocytopenia, leukopenia and the like.

The invention discloses coarse cereal health medicinal instant granules having an effect of anemia symptom improving, and a production method thereof. The coarse cereal health medicinal instant granules comprise main materials and auxiliary materials, wherein the main materials comprise the following raw materials 10 parts of angelica sinensis, 5 parts of cynanchum otophyllum, 5 parts of radix rehmanniae preparata, 8 parts of ligusticum chuanxiong hort, 20 parts of red date, 20 parts of red beans, 20 parts of red peanut, and 15 parts of Chinese wolfberry, and the auxiliary materials comprise the following raw materials 5 parts of tomato, 5 parts of celery, 5 parts of pig liver, 10 parts of cherry, 5 parts of black fungus powder, 5 parts of black sesame powder, and 6 parts of brown sugar. According to the present invention, the coarse cereal health medicinal instant granules provide significant effects for erythropoiesis reducing anemia and hemolytic anemia, and has advantages of anemia symptom relieving and treating, remarkable effect, no side effect, safety, reliability, easy use, complete nutrition supplementing, physical fitness improving, and immunity improving.

The invention discloses a nifedipine pharmaceutical composition. The nifedipine pharmaceutical composition is prepared from nifedipine and a natural product compound (I) of a novel structure, and the nifedipine compound (I) has a treatment effect on haemolytic anaemia when acting independently; the treatment effect on haemolytic anaemia is further improved when nifedipine and the compound (I) act jointly, nifedipine and the compound (I) can be developed into medicine for treating haemolytic anaemia, and compared with the prior art, an outstanding substantive feature and a remarkable progress are achieved. The compound (I) is shown in the description.

The present invention relates to the use of suppressive macrophage or dendritic cells (activated with C-reactive protein or CRP-related compounds), for the treatment of various disease states and conditions associated with immune thrombocytopenic purpura (ITP) and/or systemic lupus erythematosus (SLE), including lupus of the skin (discoid), systemic lupus of the joints, lungs and kidneys, hematological conditions including hemolytic anemia and low lymphocyte counts, lymphadenopathy and CNS effects, including memory loss, seizures and psychosis, among numerous others as otherwise disclosed herein. In another aspect of the invention, the reduction in the likelihood that a patient who is at risk for an outbreak of a disease state or condition associated with systemic lupus erythematosus or ITP will have an outbreak is an additional aspect of the present invention. In the case of ITP, methods of the present invention are used to increase platelet counts in the treated patient. In addition, in the case of ITP, the present invention relates to the use of CRP or a CRP-related compound in the absence of suppressive macrophages for the treatment of ITP.

The invention belongs to a pharmaceutical composition for treating hemolytic anemia and application thereof. The pharmaceutical composition is prepared from the following raw materials: processed radix aconiti lateralis, herba cistanche, herba epimedii, radix morindae officinalis, rhizoma coptidis, radix scutellariae, cortex phellodendri, semen plantaginis, rhizoma imperatae and fructus gardeniae. The pharmaceutical composition has the advantages of stable quality control and obvious treatment effect, can warm and invigorate kidney yang to help the spleen and the stomach to decompose food, can enable the spleen transportation function to be normal and block the damp-heat source, can clear damp-heat to achieve the effect of treating both symptoms and root causes, and has high cure rate.

The invention discloses a pharmaceutical composition for treating hemolytic anemia and an application of the pharmaceutical composition. The active ingredient in the pharmaceutical composition is composed of montelukast sodium and ciclosporin, the montelukast sodium and the ciclosporin bring an obvious synergistic effect through different effect targets in the treatment of the hemolytic anemia, and the side effects and adverse reaction rate of the montelukast sodium are low, the dosage of the ciclosporin is only one-fifth of a conventional dosage, so that the cost of medication, side effects and adverse reaction rate are greatly reduced, and the safety and compliance of patient medication are increased.